BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/29/2014 11:31:00 AM | Browse: 393 | Download: 469
Publication Name World Journal of Gastroenterology
Manuscript ID 5390
Country/Territory Japan
Received
2013-09-04 17:09
Peer-Review Started
2013-09-05 09:07
To Make the First Decision
2013-12-26 11:23
Return for Revision
2013-11-14 10:42
Revised
2013-11-20 09:02
Second Decision
2014-02-27 11:13
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-27 11:36
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-03-19 10:39
Publish the Manuscript Online
2014-04-17 13:27
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Topic Highlights
Article Title Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age
Manuscript Source Invited Manuscript
All Author List Koji Miyahara, Kazuhiro Nouso and Kazuhide Yamamoto
Funding Agency and Grant Number
Corresponding author Koji Miyahara, MD, PhD, Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama 700-8558, Japan. mkojisup@yahoo.co.jp
Keywords Biomarker; Molecular targeted therapy; Clinical trial; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Sorafenib
Core Tip Sorafenib is the only systemic therapy proven to have a positive effect on survival and to be well tolerated in patients with advanced hepatocellular carcinoma (HCC). We summarize the most current status of sorafenib therapy, focusing on (1) safety and efficacy of sorafenib for advanced HCC; (2) biomarkers predicting efficacy of sorafenib; (3) expanded application for the treatment of non-advanced HCC; (4) sorafenib efficacy beyond radiological progression; and (5) novel therapeutics and hepatic arterial infusion chemotherapy.
Publish Date 2014-04-17 13:27
Citation Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol 2014; 20(15): 4151-4159
Url http://www.wjgnet.com/1007-9327/full/v20/i15/4151.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i15.4151
Full Article (PDF) WJG-20-4151.pdf
Full Article (Word) WJG-20-4151.doc
Manuscript File 5390-Review.docx
Answering Reviewers 5390-Answering reviewers.pdf
Copyright License Agreement 5390-Copyright assignment.pdf
Peer-review Report 5390-Peer review(s).pdf
Scientific Editor Work List 5390-Scientific editor work list.doc